Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on February 3, 2009. The report discloses interim appointments to key executive roles effective immediately.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to executive compensation:
- Interim CFO Compensation: Mark N.K. Bagnall will be compensated at a rate of $200 per hour, capped at $8,000 in the aggregate.
Material Changes
The primary material change is the appointment of interim officers:
- Principal Executive Officer (Interim): Brian M. Culley, previously Chief Business Officer and Senior Vice President.
- Principal Financial and Accounting Officer (Interim): Mark N.K. Bagnall, previously a Board member and consultant (and former CFO from April 2008 to December 2008).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or specific risk factors. It focuses solely on the corporate governance change and the professional backgrounds of the newly appointed interim officers.
Investor Verification Checklist
- Verify the reason for the interim appointments (e.g., departure of previous CEO/CFO).
- Confirm the duration of the interim roles and plans for permanent replacements.
- Review recent 10-Q or 10-K filings for actual financial performance, as this 8-K contains no operational metrics.
- Check for any pending litigation or regulatory issues that may have triggered the leadership change.